| Identification | Back Directory | [Name]
2-Pyrazinecarbonitrile, 4-[(1S)-1-cyclopropyl-2-Methoxyethyl]-6-[[6-(difluoroMethoxy)-2,5-diMethyl-3-pyridinyl]aMino]-4,5-dihydro-5-oxo- | [CAS]
1188407-45-5 | [Synonyms]
BMS-764459
BMS-764459 >=98% (HPLC)
4-[(1S)-1-cyclopropyl-2-methoxyethyl]-6-[[6-(difluoromethoxy)-2,5-dimethylpyridin-3-yl]amino]-5-oxopyrazine-2-carbonitrile
2-Pyrazinecarbonitrile, 4-[(1S)-1-cyclopropyl-2-Methoxyethyl]-6-[[6-(difluoroMethoxy)-2,5-diMethyl-3-pyridinyl]aMino]-4,5-dihydro-5-oxo- | [Molecular Formula]
C19H21F2N5O3 | [MDL Number]
MFCD18642630 | [MOL File]
1188407-45-5.mol | [Molecular Weight]
405.399 |
| Hazard Information | Back Directory | [Description]
BMS-764459 is a novel potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1). | [Uses]
BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer[1][2]. | [References]
[1] David K. Leahy, et al. Development of an Efficient Synthesis of Two CRF Antagonists for the Treatment of Neurological Disorders. Org. Process Res. Dev. 2010, 14, 5, 1221-1228.
[2] Simic D, et al. MicroRNA changes associated with atypical CYP1A1 inducer BMS-764459. Toxicology. 2013 Sep 15;311(3):169-77. DOI:10.1016/j.tox.2013.06.006 |
|
|